In conclusion, in mouse models, our compelling results show that CCR3 is therefore a major determinant of prostate cancer progression by influencing tumour size and adipose tissue remodelling and that its effect is substantially influenced by obesity. Here, CCR3 is linked to prostate carcinoma.